WallStSmart

BlackRock Health Sciences Trust II (BMEZ)vsBrookfield Corp (BN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BN leads profitability with a 1.7% profit margin vs 0.0%. BMEZ trades at a lower P/E of 5.7x. BN earns a higher WallStSmart Score of 63/100 (C+).

BMEZ

Avoid

30

out of 100

Grade: F

Growth: 3.3Profit: 4.0Value: 6.7Quality: 6.0
Piotroski: 3/9

BN

Buy

63

out of 100

Grade: C+

Growth: 6.0Profit: 5.5Value: 4.3Quality: 4.0
Piotroski: 5/9Altman Z: 0.64

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BMEZ2 strengths · Avg: 10.0/10
P/E RatioValuation
5.7x10/10

Attractively priced relative to earnings

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

BN4 strengths · Avg: 8.8/10
EPS GrowthGrowth
158.8%10/10

Earnings expanding 158.8% YoY

Market CapQuality
$101.83B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
28.9%8/10

Strong operational efficiency at 28.9%

Areas to Watch

BMEZ4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$904.39M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
5.7%3/10

ROE of 5.7% — below average capital efficiency

BN4 concerns · Avg: 2.5/10
Return on EquityProfitability
2.8%3/10

ROE of 2.8% — below average capital efficiency

Profit MarginProfitability
1.7%3/10

1.7% margin — thin

P/E RatioValuation
89.4x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-5.60B2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : BMEZ

The strongest argument for BMEZ centers on P/E Ratio, Debt/Equity.

Bull Case : BN

The strongest argument for BN centers on EPS Growth, Market Cap, Price/Book. PEG of 1.27 suggests the stock is reasonably priced for its growth.

Bear Case : BMEZ

The primary concerns for BMEZ are Revenue Growth, EPS Growth, Market Cap.

Bear Case : BN

The primary concerns for BN are Return on Equity, Profit Margin, P/E Ratio. A P/E of 89.4x leaves little room for execution misses. Debt-to-equity of 5.72 is elevated, increasing financial risk.

Key Dynamics to Monitor

BN is growing revenue faster at 7.9% — sustainability is the question.

BMEZ generates stronger free cash flow (79M), providing more financial flexibility.

Monitor ASSET MANAGEMENT industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BN scores higher overall (63/100 vs 30/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BlackRock Health Sciences Trust II

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

BlackRock Health Sciences Trust II (BMEZ) is a closed-end fund designed to deliver high total returns by investing in a diversified portfolio focused primarily on the health sciences sector, encompassing pharmaceuticals, biotechnology, and medical devices. Backed by BlackRock's extensive investment management experience, BMEZ seeks to capitalize on substantial growth prospects driven by demographic shifts and increasing healthcare spending. The fund's disciplined and strategic investment approach positions it as a compelling choice for institutional investors looking to enhance their portfolios while navigating the dynamic and innovative landscape of the health sciences industry.

Brookfield Corp

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

Brookfield Corporation is an alternative asset manager and REIT/Real Estate Investment Manager firm focuses on real estate, renewable power, infrastructure and venture capital and private equity assets. The company is headquartered in Toronto, Canada with additional offices across Northern America; South America; Europe; Middle East and Asia.

Want to dig deeper into these stocks?